Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maria Mitsogianni, Athanasios Papatsoris, Vanessa-Meletia Bala, Hussein Issa, Mohammad Moussa & Iraklis Mitsogiannis. (2023) An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 24:16, pages 1765-1774.
Read now
Read now
Ola Bratt, Stefan Carlsson, Per Fransson, Jon Kindblom, Johan Stranne & Camilla Thellenberg Karlsson. (2022) The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scandinavian Journal of Urology 56:4, pages 278-284.
Read now
Read now
Ju-Ha Kim, Hyemin Lee, Eun Ah Shin, Dong Hee Kim, Jhin Baek Choi & Sung-Hoon Kim. (2017) Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression. Expert Opinion on Therapeutic Targets 21:9, pages 911-920.
Read now
Read now
Articles from other publishers (44)
Marina N. Sharifi, Ruth M. O'Regan & Kari B. Wisinski. (2023) Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?. Clinical Breast Cancer 23:8, pages 813-824.
Crossref
Crossref
Nishita Tripathi, Vinay Mathew Thomas, Nicolas Sayegh, Georges Gebrael, Beverly Chigarira, Yeonjung Jo, Haoran Li, Kamal K. Sahu, Roberto Nussenzveig, Blake Nordblad, Umang Swami, Neeraj Agarwal & Benjamin L. Maughan. (2023) Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer. The Prostate 83:16, pages 1602-1609.
Crossref
Crossref
Seyed Hossein Abtahi Eivary, Ramiar Kamal Kheder, Soran K. Najmaldin, Nahid Kheradmand, Seyed-Alireza Esmaeili & Jafar Hajavi. (2023) Implications of IL-21 in solid tumor therapy. Medical Oncology 40:7.
Crossref
Crossref
Helena Järemo, Julius Semenas, Sofia Halin Bergström, Marie Lundholm, Elin Thysell, Anders Widmark, Sead Crnalic, Erik Bovinder Ylitalo, Anders Bergh, Maria Brattsand & Pernilla Wikström. (2023) Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328. Cancers 15:9, pages 2437.
Crossref
Crossref
Tina Petrić & Maja Sabol. (2023) Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer. International Journal of Molecular Sciences 24:6, pages 5293.
Crossref
Crossref
Nicolas Sayegh, Nishita Tripathi, Roberto H. Nussenzveig, Vinay Mathew Thomas, Clara Tandar, Divyam Goel, Blake Nordblad, Kamal Kant Sahu, Haoran Li, Benjamin L. Maughan, Neeraj Agarwal & Umang Swami. (2023) Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. European Urology Focus 9:1, pages 106-109.
Crossref
Crossref
Dawid Wardecki, Małgorzata Dołowy, Katarzyna Bober-Majnusz & Josef Jampilek. (2022) Comparative Study of the Lipophilicity of Selected Anti-Androgenic and Blood Uric Acid Lowering Compounds. Molecules 28:1, pages 166.
Crossref
Crossref
Giorgia Gurioli, Vincenza Conteduca, Nicole Brighi, Emanuela Scarpi, Umberto Basso, Giuseppe Fornarini, Alessandra Mosca, Maurizio Nicodemo, Giuseppe Luigi Banna, Cristian Lolli, Giuseppe Schepisi, Giorgia Ravaglia, Isabella Bondi, Paola Ulivi & Ugo De Giorgi. (2022) Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. BMC Medicine 20:1.
Crossref
Crossref
Miao Liu, Shiguo Liu & Feng Chen. (2022) WWC1, a target of miR-138-5p, facilitates the progression of prostate cancer. The American Journal of the Medical Sciences 364:6, pages 772-781.
Crossref
Crossref
Sunil Rajput, Desmond Pink, Scott Findlay, Emma Woolner, John D. Lewis & Mark T. McDermott. (2022) Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. ACS Sensors 7:3, pages 827-838.
Crossref
Crossref
Heng Li, Yucong Zhang, Dong Li, Xin Ma, Kai Xu, Beichen Ding, Hongzhao Li, Zhize Wang, Wei Ouyang, Gongwei Long, Jin Zeng, Haoran Liu, Libin Yan, Yangjun Zhang, Zheng Liu, Wei Guan, Zhiquan Hu, Cong Liu, Jie Wan, Guoping Wang, Xiaoyong Pu, Minghui Zhang, Linlang Guo, Ruihua An, Jiping Qi, Aitao Guo, Zhangqun Ye, Jiumin Liu, Xu Zhang & Hua Xu. (2021) Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. European Urology 79:6, pages 879-886.
Crossref
Crossref
Joshua Altschuler, Jennifer A. Stockert & Natasha Kyprianou. (2021) Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. International Journal of Molecular Sciences 22:4, pages 2100.
Crossref
Crossref
Mariana Morais, Vera Machado, Francisca Dias, Carlos Palmeira, Gabriela Martins, Magda Fonseca, Catarina S. M. Martins, Ana Luísa Teixeira, João A. V. Prior & Rui Medeiros. (2021) Starch-Capped AgNPs’ as Potential Cytotoxic Agents against Prostate Cancer Cells. Nanomaterials 11:2, pages 256.
Crossref
Crossref
Mani Arulkumar, Varatharajan Mathivanan, Ramalingam Revathi & Zhao-Yang Wang. 2021. Nanotechnology in Medicine. Nanotechnology in Medicine
105
121
.
Mariana Morais, Ana Luísa Teixeira, Francisca Dias, Vera Machado, Rui Medeiros & João A. V. Prior. (2020) Cytotoxic Effect of Silver Nanoparticles Synthesized by Green Methods in Cancer. Journal of Medicinal Chemistry 63:23, pages 14308-14335.
Crossref
Crossref
Jingqian Guan, Xizi Jiang, Junda Gai, Xiaodan Sun, Jinming Zhao, Ji Li, Yizhuo Li, Ming Cheng, Tengjiao Du, Lin Fu & Qingchang Li. (2020) Sirtuin 5 regulates the proliferation, invasion and migration of prostate cancer cells through acetyl‐CoA acetyltransferase 1. Journal of Cellular and Molecular Medicine 24:23, pages 14039-14049.
Crossref
Crossref
Fabrizio Fontana, Michela Raimondi, Monica Marzagalli, Michele Sommariva, Nicoletta Gagliano & Patrizia Limonta. (2020) Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery. International Journal of Molecular Sciences 21:18, pages 6806.
Crossref
Crossref
Jos� Guzman‑Esquivel, Martha Mendoza‑Hernandez, Daniel Tiburcio‑Jimenez, Oscar Avila‑Zamora, Josuel Delgado‑Enciso, Luis De‑Leon‑Zaragoza, Juan Casarez‑Price, Iram Rodriguez‑Sanchez, Margarita Martinez‑Fierro, Carmen Meza‑Robles, Alejandro Barocio‑Acosta, Luz Baltazar‑Rodriguez, Sergio Zaizar‑Fregoso, Jorge Plata‑Florenzano & Iv�n Delgado‑Enciso. (2020) Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial. Oncology Letters.
Crossref
Crossref
Benjamin L. Maughan & Emmanuel S. Antonarakis. (2020) Does sequencing order of antiandrogens in prostate cancer matter?. Nature Reviews Urology 17:4, pages 197-198.
Crossref
Crossref
F. König, A. Strauß, M. Johannsen, C. Mommsen, E. Fricke, J. Klier, S. Mehl, D. Pfister, C.-O. Sahlmann, A. Werner & P. J. Goebell. (2019) Radium-223 zur Therapie des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC)Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Der Urologe 59:1, pages 53-64.
Crossref
Crossref
Janeen H. Trembley, Betsy T. Kren, Md. J. Abedin, Daniel P. Shaughnessy, Yingming Li, Scott M. Dehm & Khalil Ahmed. (2019) CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression. Pharmaceuticals 12:2, pages 89.
Crossref
Crossref
Bin Yang, Wenyu Zhang, Daju Sun, Xin Wei, Youpeng Ding, Yanan Ma & Zhixin Wang. (2019) Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5. Biomedicine & Pharmacotherapy 109, pages 2128-2135.
Crossref
Crossref
E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger & Fernand Labrie. (2018) Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. Journal of Urology 200:5, pages 956-966.
Crossref
Crossref
Christof Bernemann, Julie Steinestel, Verena Humberg, Martin Bögemann, Andres Jan Schrader & Jochen K. Lennerz. (2018) Performance comparison of two androgen receptor splice variant 7 (AR‐V7) detection methods. BJU International 122:2, pages 219-226.
Crossref
Crossref
Neal D. Shore, Teuvo L. Tammela, Christophe Massard, Petri Bono, John Aspegren, Mika Mustonen & Karim Fizazi. (2018) Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. European Urology Focus 4:4, pages 547-553.
Crossref
Crossref
Benjamin L. Maughan, Liana B. Guedes, Kenneth Boucher, Gaurav Rajoria, Zach Liu, Szczepan Klimek, Roberto Zoino, Emmanuel S. Antonarakis & Tamara L. Lotan. (2018) p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 21:2, pages 260-268.
Crossref
Crossref
Avital Lev, Amriti R. Lulla, Brian C. Ross, Marie D. Ralff, Petr B. Makhov, David T. Dicker & Wafik S. El-Deiry. (2018) ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Molecular Cancer Research 16:5, pages 754-766.
Crossref
Crossref
Liancheng Fan, Rui Wang, Chenfei Chi, Wen Cai, Yong Zhang, Hongyang Qian, Xiaoguang Shao, Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Lixin Zhou, Baijun Dong & Wei Xue. (2018) Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. The Prostate 78:4, pages 250-256.
Crossref
Crossref
Yiqiao Huang, Xianhan Jiang, Xue Liang & Ganggang Jiang. (2018) Molecular and cellular mechanisms of castration resistant prostate cancer (Review). Oncology Letters.
Crossref
Crossref
Zoran Culig & Martin Puhr. (2018) Interleukin-6 and prostate cancer: Current developments and unsolved questions. Molecular and Cellular Endocrinology 462, pages 25-30.
Crossref
Crossref
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott, Sebastian Schmid, Ramona Secci, Margitta Retz, Jürgen E. Gschwend, Jürgen Ruland, Christof Winter & Matthias M. Heck. (2017) AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. European Urology 72:5, pages 828-834.
Crossref
Crossref
Naoki Terada, Benjamin L Maughan, Shusuke Akamatsu, Takashi Kobayashi, Toshinari Yamasaki, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa & Emmanuel S Antonarakis. (2017) Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. International Journal of Urology 24:6, pages 441-448.
Crossref
Crossref
Sanjay Hinduja, Adnan Khan & Uzair B. Chaudhary. (2017) Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. Journal of Cancer Therapy 08:13, pages 1149-1159.
Crossref
Crossref
Parvez M. Lokhandwala, Stacy L. Riel, Lisa Haley, Changxue Lu, Yan Chen, John Silberstein, Yezi Zhu, Gang Zheng, Ming-Tseh Lin, Christopher D. Gocke, Alan W. Partin, Emmanuel S. Antonarakis, Jun Luo & James R. Eshleman. (2017) Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. The Journal of Molecular Diagnostics 19:1, pages 115-125.
Crossref
Crossref
Mayumi Okamoto, Kyosuke Naka, Kiichi Ishiwata, Isao Shimizu & Jun Toyohara. (2016) Synthesis and basic evaluation of 7α-(3-[18F]fluoropropyl)-testosterone and 7α-(3-[18F]fluoropropyl)-dihydrotestosterone. Annals of Nuclear Medicine 31:1, pages 53-62.
Crossref
Crossref
Benjamin L. Maughan, Brandon Luber, Rosa Nadal & Emmanuel S. Antonarakis. (2017) Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. The Prostate 77:1, pages 33-40.
Crossref
Crossref
Vasiliki Pelekanou & Elias Castanas. (2016) Androgen Control in Prostate Cancer. Journal of Cellular Biochemistry 117:10, pages 2224-2234.
Crossref
Crossref
Thirupandiyur S. Udayakumar, Radka Stoyanova, Mohammed M. Shareef, Zhaomei Mu, Sakhi Philip, Kerry L. Burnstein & Alan Pollack. (2016) Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. Molecular Cancer Therapeutics 15:6, pages 1353-1363.
Crossref
Crossref
Rosa Nadal, Hua-Ling Tsai, Victoria J. Sinibaldi, Channing J. Paller, Emmanuel S. Antonarakis, Sammuel R. Denmeade, Michael A. Carducci & Mario A. Eisenberger. (2016) Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. The Prostate 76:5, pages 512-520.
Crossref
Crossref
Karim BoudadiEmmanuel S. Antonarakis. (2016) Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology 10s1, pages CMO.Ss34534.
Crossref
Crossref
Benjamin L. Maughan & Emmanuel S. Antonarakis. (2015) Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Current Treatment Options in Oncology 16:12.
Crossref
Crossref
Benjamin L. Maughan, Xian C. Xhou, Daniel L. Suzman, Rosa Nadal, Sunakshi Bassi, Michael T. Schweizer & Emmanuel S. Antonarakis. (2015) Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. The Prostate 75:15, pages 1814-1820.
Crossref
Crossref
Margaret M Centenera, Sarah L Carter, Joanna L Gillis, Deborah L Marrocco-Tallarigo, Randall H Grose, Wayne D Tilley & Lisa M Butler. (2015) Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer 22:5, pages 805-818.
Crossref
Crossref
Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang & Ke Chen. (2015) Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Clinical Cancer Research 22:6, pages 1531-1544.
Crossref
Crossref